Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes

This international, randomized, double‐blind trial (NCT01864174) compared the efficacy and safety of metformin extended‐release (XR) and immediate‐release (IR) in patients with type 2 diabetes. After a 4‐week placebo lead‐in, pharmacotherapy‐naïve adults with glycated haemoglobin (HbA1c) at 7.0% to...

Descripción completa

Detalles Bibliográficos
Autores: Aggarwal, Naresh, Singla, Anuj, Mathieu, Chantal, Montanya Mias, Eduard, Pfeiffer, Andreas F. H., Johnsson, Eva, Zhao, June, Iqbal, Nayyar, Bailey, Clifford
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/124028
Acceso en línea:https://hdl.handle.net/2445/124028
Access Level:acceso abierto
Palabra clave:Diabetis
Hemoglobina
Metformina
Diabetes
Hemoglobin
Metformin
id ES_0f42583eaeb161908519c7f748e44b3d
oai_identifier_str oai:diposit.ub.edu:2445/124028
network_acronym_str ES
network_name_str España
repository_id_str
spelling Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetesAggarwal, NareshSingla, AnujMathieu, ChantalMontanya Mias, EduardPfeiffer, Andreas F. H.Johnsson, EvaZhao, JuneIqbal, NayyarBailey, CliffordDiabetisHemoglobinaMetforminaDiabetesHemoglobinMetforminThis international, randomized, double‐blind trial (NCT01864174) compared the efficacy and safety of metformin extended‐release (XR) and immediate‐release (IR) in patients with type 2 diabetes. After a 4‐week placebo lead‐in, pharmacotherapy‐naïve adults with glycated haemoglobin (HbA1c) at 7.0% to 9.2% were randomized (1:1) to receive once‐daily metformin XR 2000 mg or twice‐daily metformin IR 1000 mg for 24 weeks. The primary endpoint was change in HbA1c after 24 weeks. Secondary endpoints were change in fasting plasma glucose (FPG), mean daily glucose (MDG) and patients (%) with HbA1c <7.0% after 24 weeks. Overall, 539 patients were randomized (metformin XR, N = 268; metformin IR, N = 271). Adjusted mean changes in HbA1c, FPG, MDG and patients (%) with HbA1c <7.0% after 24 weeks were similar for XR and IR: −0.93% vs −0.96%; −21.1 vs −20.6 mg/dL (−1.2 vs −1.1 mmol/L); −24.7 vs −27.1 mg/dL (−1.4 vs −1.5 mmol/L); and 70.9% vs 72.0%, respectively. Adverse events were similar between groups and consistent with previous studies. Overall, metformin XR demonstrated efficacy and safety similar to that of metformin IR over 24 weeks, with the advantage of once‐daily dosing.John Wiley & Sons2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/124028Articles publicats en revistes (Ciències Clíniques)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1111/dom.13104Diabetes Obesity and Metabolism, 2017, vol. 20, num. 2, p. 463-467https://doi.org/10.1111/dom.13104cc-by-nc (c) Aggarwal, Naresh et al., 2017http://creativecommons.org/licenses/by-nc/3.0/esinfo:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1240282026-05-27T06:46:51Z
dc.title.none.fl_str_mv Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes
title Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes
spellingShingle Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes
Aggarwal, Naresh
Diabetis
Hemoglobina
Metformina
Diabetes
Hemoglobin
Metformin
title_short Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes
title_full Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes
title_fullStr Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes
title_full_unstemmed Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes
title_sort Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes
dc.creator.none.fl_str_mv Aggarwal, Naresh
Singla, Anuj
Mathieu, Chantal
Montanya Mias, Eduard
Pfeiffer, Andreas F. H.
Johnsson, Eva
Zhao, June
Iqbal, Nayyar
Bailey, Clifford
author Aggarwal, Naresh
author_facet Aggarwal, Naresh
Singla, Anuj
Mathieu, Chantal
Montanya Mias, Eduard
Pfeiffer, Andreas F. H.
Johnsson, Eva
Zhao, June
Iqbal, Nayyar
Bailey, Clifford
author_role author
author2 Singla, Anuj
Mathieu, Chantal
Montanya Mias, Eduard
Pfeiffer, Andreas F. H.
Johnsson, Eva
Zhao, June
Iqbal, Nayyar
Bailey, Clifford
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Diabetis
Hemoglobina
Metformina
Diabetes
Hemoglobin
Metformin
topic Diabetis
Hemoglobina
Metformina
Diabetes
Hemoglobin
Metformin
description This international, randomized, double‐blind trial (NCT01864174) compared the efficacy and safety of metformin extended‐release (XR) and immediate‐release (IR) in patients with type 2 diabetes. After a 4‐week placebo lead‐in, pharmacotherapy‐naïve adults with glycated haemoglobin (HbA1c) at 7.0% to 9.2% were randomized (1:1) to receive once‐daily metformin XR 2000 mg or twice‐daily metformin IR 1000 mg for 24 weeks. The primary endpoint was change in HbA1c after 24 weeks. Secondary endpoints were change in fasting plasma glucose (FPG), mean daily glucose (MDG) and patients (%) with HbA1c <7.0% after 24 weeks. Overall, 539 patients were randomized (metformin XR, N = 268; metformin IR, N = 271). Adjusted mean changes in HbA1c, FPG, MDG and patients (%) with HbA1c <7.0% after 24 weeks were similar for XR and IR: −0.93% vs −0.96%; −21.1 vs −20.6 mg/dL (−1.2 vs −1.1 mmol/L); −24.7 vs −27.1 mg/dL (−1.4 vs −1.5 mmol/L); and 70.9% vs 72.0%, respectively. Adverse events were similar between groups and consistent with previous studies. Overall, metformin XR demonstrated efficacy and safety similar to that of metformin IR over 24 weeks, with the advantage of once‐daily dosing.
publishDate 2017
dc.date.none.fl_str_mv 2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/124028
url https://hdl.handle.net/2445/124028
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1111/dom.13104
Diabetes Obesity and Metabolism, 2017, vol. 20, num. 2, p. 463-467
https://doi.org/10.1111/dom.13104
dc.rights.none.fl_str_mv cc-by-nc (c) Aggarwal, Naresh et al., 2017
http://creativecommons.org/licenses/by-nc/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc (c) Aggarwal, Naresh et al., 2017
http://creativecommons.org/licenses/by-nc/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv John Wiley & Sons
publisher.none.fl_str_mv John Wiley & Sons
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403443957858304
score 15,300719

Similares en LA Referencia